By Robin Respaut and Maggie Fick SAN FRANCISCO (Reuters) -In what she calls the "wild west" of obesity medicines, ...

People with type 1 diabetes who need to lose weight can benefit from the blockbuster GLP-1 drug semaglutide currently ...

Novo Nordisk said on Thursday it will collaborate with WeightWatchers to sell its blockbuster weight-loss drug Wegovy, ...

For reference, Novo Nordisk also offers a highly successful weight loss drug, Wegovy, a GLP-1 receptor agonist.

Under the deal, cash-paying patients can access a month’s supply of Wegovy through the Danish drugmaker’s Novocare pharmacy for $299. The one-time price will also be available through Novo’s other ...

Novo Nordisk has bounced back from a sour ending to its Hims & Hers partnership, revealing a new deal with WeightWatchers to ...

Novo Nordisk has launched its weight-loss drug Wegovy in India, while Eli Lilly's Mounjaro has received regulatory approval, ...

Novo Nordisk continues to expand its partnerships with telehealth companies to broaden access to its blockbuster weight loss ...

Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...

The stock's market-beating momentum has come crashing to a halt, following shocking allegations from one of the world's largest pharmaceutical companies.

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

With Novo Nordisk’s Wegovy already in the market, Eli Lilly is stepping up its game with a patient-friendly pen device, ...